Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | PTGES | O14684 | 9/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027526 | 0.93 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2C19KCNH2EPHX2 | |
| SCHEMBL13634086 | 0.93 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2C19PTGESEPHX2 | |
| SCHEMBL3027159 | 0.93 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19KCNH2EPHX2 | |
| SCHEMBL3796786 | 0.93 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19PTGESEPHX2 | |
| SCHEMBL3031515 | 0.93 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19KCNH2PTGES | |
| SCHEMBL3034593 | 0.93 | CYP3A4 (0.46) | CYP3A4CYP2C9CYP2C19KCNH2PTGES | |
| SCHEMBL3031620 | 0.93 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19KCNH2PTGES | |
| SCHEMBL3023375 | 0.92 | CYP3A4 (0.45) | CYP3A4CYP2C9CYP2C19KCNH2PTGES | |
| SCHEMBL3016690 | 0.92 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19KCNH2PTGES | |
| SCHEMBL3030461 | 0.92 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19KCNH2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | CYP3A4 169/4885CYP2C9 720/4885CYP2C19 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.